Skip to Main Content

Author Details

Paul Wheatley-Price
The Ottawa Hospital Research Institute
2005
95
27
PMIDPaper TitleJournal TitlePublished Year
36841541Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).J Thorac Oncol2023
37754522What Attributes Matter Most in Physicians? Exploratory Findings from a Single-Centre Survey of Stakeholder Priorities in Cancer Care at a Canadian Academic Cancer Centre.Curr Oncol2023
37582243Medical Assistance in Dying in Patients With Cancer.JCO Oncol Pract2023
37504341Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.Curr Oncol2023
37504336Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.Curr Oncol2023
37504325Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.Curr Oncol2023
37504310Management of Very Early Small Cell Lung Cancer: A Canadian Survey Study.Curr Oncol2023
37814061ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.Nat Med2023
37185402Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial.Curr Oncol2023
37100730A rare case of false negative ROS1 fusion in metastatic pulmonary adenocarcinoma: Case report and lessons learned.Clin Lung Cancer2023
33432468Assessment of Patient Satisfaction Among Cancer Patients Undergoing Radiotherapy.J Cancer Educ2022
35510132The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma.JTO Clin Res Rep2022
35529290Complex Germline K757N Mutation in Non-Small-Cell Lung Cancer: A Case Report.Case Rep Oncol2022
35523040Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis.Cancer Treat Res Commun2022
36661657Stereotactic Body Radiotherapy (SBRT) in Very Limited-Stage Small Cell Lung Cancer (VLS-SCLC).Curr Oncol2022
35923926The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.Ther Adv Med Oncol2022
36290875Access to Cancer Drugs in Canada.Curr Oncol2022
35251320Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer.Ther Adv Med Oncol2022
35200582Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models.Curr Oncol2022
35200541The Pathway for New Cancer Drug Access in Canada.Curr Oncol2022
34965945Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.Clin Cancer Res2022
35199055Brief Report: Medical Assistance in Dying in Patients With Lung Cancer.JTO Clin Res Rep2022
35323362Determinants of the Cancer Drug Funding Process in Canada.Curr Oncol2022
33383487Chemotherapy for Non-Small Cell Lung Cancer in the Intensive Care Unit.Cancer Treat Res Commun2021
33893043Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience.Clin Lung Cancer2021
33747958The Diminishing Importance of Primary Site Identification in Cancer of Unknown Primary: A Canadian Single-Center Experience.Front Oncol2021
33720756Challenges of Immunotherapy in Stage IV Non-Small-Cell Lung Cancer.JCO Oncol Pract2021
34898564Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLC.Curr Oncol2021
34436567Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity.JAMA Oncol2021
34381713The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience.Front Oncol2021
34804219The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.Ther Adv Med Oncol2021
34716002EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.J Thorac Oncol2021
34353680The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.Lung Cancer2021
31506392Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.Oncologist2020
33704175Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer.Curr Oncol2020
32020438A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.Invest New Drugs2020
33310367Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.Cancer Treat Res Commun2020
32702570Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.Lung Cancer2020
32218658Analyzing the effect of physician assignment in the survival of patients with advanced non-small-cell lung cancer.Curr Oncol2020
32169783A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.Lung Cancer2020
32489252The most important attribute: stakeholder perspectives on what matters most in a physician.Curr Oncol2020
30685114Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.Clin Lung Cancer2019
31200828Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.Lung Cancer2019
30927666Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.Cancer Treat Res Commun2019
30506102A prospective intervention to improve happiness and reduce burnout in oncologists.Support Care Cancer2019
28711384Radical Treatment of Stage II Non-small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes.Clin Lung Cancer2018
29804902Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.Lancet Oncol2018
30111974Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?Curr Oncol2018
29545095Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Lancet Oncol2018
29601671The importance of greater speed in drug development for advanced malignancies.Cancer Med2018
  • 1 - 50 of 95

Recommended Authors

Philip E Lammers
Baptist Cancer Center
Career Start Year 2013
Number of shared co-authors 0
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 1
Marliese Alexander
Department of Pharmacy, 5Peter MacCallum Cancer Centre
Career Start Year 2011
Number of shared co-authors 1
Sara Kuruvilla
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2010
Number of shared co-authors 7
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Saiama N Waqar
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 1
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 2
Sunita Ghosh
Cross Cancer Institute
Career Start Year 2006
Number of shared co-authors 2
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 0
Daniel R Gomez
Memorial Sloan Kettering Cancer Center
Career Start Year 2005
Number of shared co-authors 2
Edward B Garon
David Geffen School of Medicine, University of California Los Angeles
Career Start Year 2005
Number of shared co-authors 1
Matthew A Gubens
University of California san francisco
Career Start Year 2003
Number of shared co-authors 0
Lecia V Sequist
Massachusetts General Hospital Cancer Center, Harvard Medical School
Career Start Year 2003
Number of shared co-authors 5
Aaron Lisberg
Jonsson Comprehensive Cancer Center, university of california los angeles
Career Start Year 2002
Number of shared co-authors 0
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 11
Daniel Morgensztern
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 0
David A Palma
University of Western Ontario
Career Start Year 2000
Number of shared co-authors 7
Drew Moghanaki
University of California Los Angeles
Career Start Year 2000
Number of shared co-authors 0
Puneeth Iyengar
UT Southwestern Medical Center, Center for Human Nutrition
Career Start Year 1996
Number of shared co-authors 0
Betty C Tong
Duke University Medical Center
Career Start Year 1996
Number of shared co-authors 0
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 4
Gregory J Riely
Memorial Sloan Kettering Cancer Center
Career Start Year 1994
Number of shared co-authors 4
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Career Start Year 1994
Number of shared co-authors 2
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 7
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 2
Pasi A J??nne
Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 5
Roy S Herbst
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 4
Giuseppe Giaccone
Meyer Cancer Center
Career Start Year 1981
Number of shared co-authors 3
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 5

Collaborators

Frances A Shepherd
University Health Network, Princess Margaret Cancer Centre
Co-authored papers 12
Geoffrey Liu
The Princess Margaret Cancer Centre/University of Toronto
Co-authored papers 10
Ming-Sound Tsao
University Health Network, University of Toronto
Co-authored papers 6
Cheryl Ho
University of British Columbia
Co-authored papers 4
Shantanu Banerji
Co-authored papers 4
Clement Ma
Co-authored papers 4
Keyue Ding
Queen's University
Co-authored papers 3
Fiona Blackhall
The University of Manchester
Co-authored papers 3
Janessa Laskin
Co-authored papers 3
Wei Xu
Princess Margaret Cancer Centre
Co-authored papers 2
Thomas John
Peter MacCallum Cancer Centre
Co-authored papers 2
David W Cescon
Princess Margaret Cancer Centre
Co-authored papers 2
Aditya Bardia
Massachusetts General Hospital Cancer Center
Co-authored papers 2
Shane White
Olivia Newton-John Cancer Wellness and Research Centre
Co-authored papers 2
Bryan Lo
The Ottawa Hospital/University of Ottawa
Co-authored papers 2
Isabelle Bairati
Laval University Cancer Research Center
Co-authored papers 1
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Co-authored papers 1
Zhuo Chen
The First Hospital of Lanzhou University
Co-authored papers 1
Abul Kalam Azad
University of Dhaka
Co-authored papers 1
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Rayjean J Hung
Lunenfeld-Tanenbaum Research Institute
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
David P Goldstein
Princess Margaret Cancer Centre/University Health Network, University of Toronto
Co-authored papers 1
Fran??ois Meyer
Laval University
Co-authored papers 1
Sharon F McGee
The Ottawa Hospital Cancer Centre
Co-authored papers 1
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 1
John Waldron
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Co-authored papers 1
Christine Massey
Princess Margaret Cancer Centre
Co-authored papers 1
Harvey Lui
University of British Columbia
Co-authored papers 1
Mun Sem Liew
The University of Melbourne
Co-authored papers 1
Release 1.2